Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
| Autor: | Merna Armanious, Isaac Rhea, Shreya Mishra, Mohammed Alomar, Kerry Ellenberg, Sara Khodor, Linh M. Duong, Kevin E. Kip, Anh Thy H. Nguyen, Justin Swanson, Michael G. Fradley, Matthew B. Schabath, Nirav Shah, Anant Kharod |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
cardio-oncology AF atrial fibrillation Cardiovascular Complication AC anticoagulation DOAC direct oral anticoagulant agent Internal medicine medicine cancer atrial fibrillation In patient Cardio oncology anticoagulation Original Research AF - Atrial fibrillation business.industry AFL atrial flutter EMR electronic medical record Cancer Atrial fibrillation medicine.disease CI confidence interval OR odds ratio Oncology MCC Moffitt Cancer Center Cardiology ECG electrocardiogram Cardiology and Cardiovascular Medicine business Atrial flutter |
| Zdroj: | JACC: CardioOncology |
| ISSN: | 2666-0873 |
| DOI: | 10.1016/j.jaccao.2020.09.008 |
| Popis: | Background Atrial fibrillation (AF) is a common cardiovascular complication affecting patients with cancer, but management strategies are not well established. Objectives The purpose of this retrospective cohort study was to evaluate cross-sectional patterns of anticoagulation (AC) use in patients with cancer with AF or atrial flutter (AFL) on the basis of their risk for stroke and bleeding. Methods Patients with cancer and electrocardiograms showing AF or AFL performed at Moffitt Cancer Center in either the inpatient or outpatient setting were included in this retrospective analysis. We described percentages of AC prescription by stroke and bleeding risk, as determined by individual CHA2DS2-VASc and HAS-BLED scores, respectively. Multivariable logistic regression evaluated clinical variables independently associated with anticoagulant prescription. Results The prevalence of electrocardiography-documented AF or AFL was 4.8% (n = 472). The mean CHA2DS2-VASc score was 2.8 ± 1.4. Among patients with CHA2DS2-VASc scores ≥2 and HAS-BLED scores Central Illustration |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|